Hospital
Methodist Fremont Health
Methodist Fremont Health was paid $7.89M by Medicaid between Oct 2018 and Dec 2024, across 154 billing codes. Its largest line is 41899, Unlisted procedure, dentoalveolar structures — 20% of everything it billed.
33Billing provider infoMETHODIST FREMONT HEALTH
FREMONT, NE 68025
FREMONT, NE 68025
33aNPI1033698543assigned 08/07/2018
33bProvider typeRural Acute Care Hospital
28Total paid$7.89M
24GClaims183,853
24DCodes billed154
24AFirst – last monthOct 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,388 | $224K | |
| 2019 | 25,735 | $827K | |
| 2020 | 22,369 | $1.17M | |
| 2021 | 43,781 | $1.69M | |
| 2022 | 48,755 | $1.76M | |
| 2023 | 29,458 | $1.61M | |
| 2024incomplete | 7,367 | $612K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 41899 | Unlisted procedure, dentoalveolar structures | 20% | 982 | 960 | $1.58M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 10,463 | 9,734 | $1.54M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.7% | 2,282 | 1,904 | $763K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 5,594 | 5,131 | $713K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 4,804 | 4,494 | $502K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 958 | 897 | $325K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 1,117 | 1,032 | $284K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 3,408 | 983 | $222K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 1,322 | 749 | $219K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 1,765 | 1,584 | $181K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 2,017 | 1,956 | $135K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 6,237 | 4,729 | $96K |
142 more codes
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 2,218 | $88K |
| 87631 | <1% | 521 | $67K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,217 | $62K |
| 80053 | Comprehensive metabolic panel | <1% | 13,120 | $59K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,030 | $53K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,382 | $50K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 166 | $48K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 228 | $46K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 815 | $44K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 204 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,230 | $34K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 96 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,385 | $29K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,449 | $27K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,060 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,516 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 579 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,586 | $23K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,270 | $21K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 433 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 323 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,947 | $20K |
| 84439 | <1% | 2,049 | $20K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 100 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,243 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,786 | $17K |
| J3490 | Unclassified drugs | <1% | 9,332 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,775 | $16K |
| 80061 | Lipid panel | <1% | 2,827 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 82 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 490 | $14K |
| 87653 | <1% | 319 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 55 | $12K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 553 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 396 | $12K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 571 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,726 | $11K |
| 87806 | <1% | 457 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 624 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,713 | $10K |
| 80050 | General health panel | <1% | 1,129 | $10K |
| G0378 | Hospital observation service, per hour | <1% | 64 | $10K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 248 | $10K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 47 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,749 | $9K |
| 82607 | <1% | 603 | $8K | |
| 87634 | <1% | 1,055 | $8K | |
| 86140 | <1% | 1,078 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 326 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $6K |
| 97161 | <1% | 129 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,404 | $6K |
| 87077 | <1% | 1,078 | $5K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 8,662 | $5K |
| 59025 | Fetal non-stress test | <1% | 15 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 712 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,434 | $5K |
| 86803 | <1% | 499 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,814 | $4K |
| 82728 | <1% | 382 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 521 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 119 | $4K |
| 81001 | <1% | 3,734 | $4K | |
| 87186 | <1% | 1,012 | $3K | |
| 87088 | <1% | 586 | $3K | |
| 85027 | <1% | 977 | $3K | |
| 83735 | <1% | 1,850 | $3K | |
| 83880 | <1% | 405 | $3K | |
| 93971 | <1% | 25 | $3K | |
| 80055 | <1% | 169 | $3K | |
| 84484 | <1% | 1,970 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 39 | $3K |
| 81025 | <1% | 1,501 | $2K | |
| 83690 | <1% | 2,032 | $2K | |
| 73630 | <1% | 56 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 20 | $2K |
| 85610 | <1% | 1,072 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 456 | $2K |
| 84145 | <1% | 405 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 74 | $2K |
| 87070 | <1% | 263 | $1K | |
| 83540 | <1% | 295 | $1K | |
| 86787 | <1% | 107 | $1K | |
| 87506 | <1% | 13 | $1K | |
| 85651 | <1% | 400 | $1K | |
| 82950 | <1% | 200 | $1K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $1K |
| 84466 | <1% | 181 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 474 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 414 | $1K |
| 86769 | <1% | 30 | $926.86 | |
| 87205 | <1% | 300 | $800.14 | |
| 81003 | <1% | 1,725 | $774.10 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 641 | $759.18 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 61 | $691.21 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 1,633 | $612.93 |
| 85379 | <1% | 696 | $610.75 | |
| 87899 | <1% | 47 | $552.67 | |
| J2704 | Injection, propofol, 10 mg | <1% | 133 | $479.00 |
| 84702 | <1% | 48 | $470.86 | |
| 82947 | <1% | 95 | $413.07 | |
| 86703 | <1% | 35 | $410.39 | |
| 86900 | <1% | 29 | $385.55 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 145 | $343.45 |
| 73562 | <1% | 45 | $299.79 | |
| 97162 | <1% | 13 | $251.70 | |
| 99156 | <1% | 386 | $225.29 | |
| 73610 | <1% | 26 | $198.43 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 55 | $186.56 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 506 | $175.51 |
| 96376 | <1% | 430 | $173.94 | |
| 82570 | <1% | 55 | $171.98 | |
| 84100 | <1% | 146 | $169.89 | |
| 86850 | <1% | 15 | $146.28 | |
| 73110 | <1% | 14 | $143.58 | |
| 82962 | <1% | 1,230 | $134.39 | |
| 82247 | <1% | 21 | $130.14 | |
| 85730 | <1% | 153 | $114.06 | |
| 83605 | <1% | 757 | $94.68 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,101 | $76.16 |
| 80143 | <1% | 314 | $72.15 | |
| 80179 | <1% | 298 | $64.04 | |
| 82077 | <1% | 114 | $63.39 | |
| 84703 | <1% | 171 | $60.26 | |
| 90686 | <1% | 48 | $55.65 | |
| 87040 | <1% | 101 | $51.80 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,260 | $51.03 |
| 90682 | <1% | 54 | $46.40 | |
| 99157 | <1% | 107 | $28.52 | |
| 82977 | <1% | 74 | $25.34 | |
| 86901 | <1% | 29 | $24.12 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 65 | $15.59 |
| 84156 | <1% | 15 | $14.07 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 196 | $12.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 334 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 127 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 12 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 228 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 28 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 13 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 32 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHMOND, BRETT (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Methodist Fremont Health | Fremont, NE | $2.74M |
| Fremont Health Clinic | Fremont, NE | $356K |
| Fremont Health Clinic | Fremont, NE | $280K |
| Methodist Fremont Health | Fremont, NE | $5K |
| Methodist Fremont Health | Fremont, NE | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.